ProBioGen and Marea Complete Sprint Project for MAR002 Clinical Material

• ProBioGen and Marea Therapeutics have successfully completed a sprint project to deliver clinical material for MAR002, an investigational anti-growth hormone receptor (GHR) antibody for acromegaly.

• The collaboration focused on an accelerated CMC program, including cell line development, process development, formulation, and GMP manufacturing services.

ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines for cardioendocrine diseases, have announced the successful completion of a sprint project to supply clinical material for MAR002. The investigational anti-growth hormone receptor (GHR) antibody is being developed for the treatment of acromegaly, a condition that can lead to serious complications.

The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program. It encompassed cell line development using ProBioGen’s CHO.RiGHT platform, process and formulation development, and GMP manufacturing. ProBioGen’s proprietary DirectedLuck transposase technology enabled high-yielding clone pools for early material production, facilitating MAR002’s progress toward clinical trials.

Dr. Alfred Merz, CEO of ProBioGen, highlighted the collaboration’s efficiency, stating, “We are pleased to have successfully completed this comprehensive project with Marea Therapeutics, delivering on our commitment to high quality and accelerated timelines.” Mark Joing, Chief Development Operations Officer of Marea, emphasized ProBioGen’s reliability and technical expertise, calling the experience “highly rewarding.”

Mark Joing, Chief Development Operations Officer of Marea, stated: “Collaborating with ProBioGen has been an incredibly valuable experience. Their deep technical expertise, commitment to quality, and exceptional reliability have reinforced our confidence in them as the ideal partner for Marea. MAR002 has the potential to be a first-in-class treatment for acromegaly, a serious and life-shortening condition with significant complications. We are grateful for ProBioGen’s support throughout this journey and look forward to working together as we move into the next phases of development.”